Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd + Nivolumab in HER2-Expressing Breast and Urothelial Cancer
NCT03523572Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2018
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of trastuzumab deruxtecan in breast cancer and urothelial carcinoma (UC) (6 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities and Objective Response Rate. Started Aug 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03523572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523572.